Europe Insulin Pen Market Size & Share 2026-2035

Europe Insulin Pen Market Size

The Europe insulin pen market was valued at USD 2.65 billion in 2025 and is expected to reach USD 2.87 billion in 2026, advancing at a 7.7% CAGR from 2026 to 2035 to total USD 5.60 billion by 2035. The market covers demand-side revenue from disposable pre-filled and reusable cartridge-based insulin pen devices, including smart connected pen systems, distributed through hospital pharmacies, retail pharmacies, and e-commerce channels across the covered European markets. Insulin drugs, cartridges, pen needles, insulin pumps, continuous glucose monitors, and standalone biosimilar formulations are outside the market scope.

The Europe insulin pen market is moving from a predominantly mechanical delivery-device market toward a differentiated care-management category. Reimbursement access, durable demand from insulin-treated populations, and the adoption of reusable and connected formats are increasing the value captured per patient, while procurement scrutiny keeps device choice closely tied to clinical utility and formulary fit.

Europe Insulin Pen Market Trends, Growth Drivers & GMI Forecast Outlook

Europe's market outlook reflects two simultaneous shifts: a broader treated diabetes population is sustaining prescription demand, while procurement and clinical workflows are redirecting value toward reusable, digitally enabled delivery systems. The pace of that transition depends on reimbursement decisions, diagnostic access, and manufacturers' ability to meet evolving regulatory requirements.

Key Drivers

*Evidence anchors use cited external data; demand implications and forecast conditions represent GMI analysis.*

A larger diagnosed patient pool creates recurring prescription demand because insulin delivery remains embedded in long-term treatment routines rather than episodic care. The commercial effect is strongest where primary-care clinicians can initiate and maintain therapy without routing every patient through specialist settings, allowing retail and digital fulfillment channels to absorb more ongoing demand.

Sustainability considerations are becoming operational procurement criteria rather than solely corporate commitments. The NHS has highlighted the material waste associated with single-use pens, increasing prescriber awareness of reusable alternatives and their potential to reduce disposal requirements ^{[2]NHS Royal Devon University Healthcare NHS Foundation Trust. "Exeter doctor campaigns to cut plastic waste through promoting reusable insulin pens." royaldevon.nhs.uk}. For manufacturers, that transition creates an incentive to pair durable pen bodies with cartridge ecosystems and patient-support services rather than compete solely on the economics of individual disposable units.

Connected pen platforms add clinical workflow value through dose capture, missed-dose alerts, and integration with glucose-data environments. Medtronic's EMEA commercial introduction of its MiniMed Go Smart MDI system and Go-Pen's CE Mark milestone demonstrate that the innovation pipeline is extending beyond conventional mechanical delivery devices ^{[3]Medtronic. "Medtronic begins EMEA commercial launch of MiniMed Go Smart MDI system with Simplera sensor." minimed.com [4]Go-Pen ApS. "Go-Pen receives CE Mark." go-pen.com}. These systems can strengthen a reimbursement case when device data supports adherence conversations and treatment decisions.

Key Restraints

*Evidence anchors use cited external data; demand implications and forecast conditions represent GMI analysis.*

Undiagnosed disease burden does not translate automatically into device demand. Until screening, diagnosis, and treatment initiation improve, patients remain outside prescription pathways, limiting the conversion of epidemiological need into market volume. This creates a particularly meaningful constraint in lower-access systems, where care infrastructure and patient follow-up can delay insulin initiation.

Payers must balance device innovation against wider diabetes-care budgets, which can slow access to premium connected pens even where clinical functionality is compelling. The result is a differentiated adoption pattern: mature reimbursement systems can assess and fund higher-value devices more readily, whereas cost-sensitive systems tend to prioritize standardized, lower-cost delivery options.

Manufacturers also face an increasingly complex compliance environment. Regulation (EU) 2025/40 raises packaging-design and documentation requirements that affect medical-device supply chains, although the treatment of sensitive medical-device packaging includes defined exemptions ^{[5]Taylor Wessing. "What the EU Packaging Regulation means for medical devices." taylorwessing.com}. Larger incumbents with established regulatory resources are better placed to absorb redesign and submission burdens, potentially widening the practical entry barrier for smaller innovators.

Europe Insulin Pen Market Segment Analysis

By Type

Disposable insulin pens generated USD 1.46 billion in 2025 and are projected to account for 40.4% of Europe Insulin Pen Market revenue by 2035. Disposable formats retain an important role in treatment initiation, acute-care pathways, and situations where pre-filled convenience reduces handling complexity. Their long-term position is increasingly shaped by environmental procurement priorities and the extent to which clinicians and patients can transition to cartridge-based regimens without compromising ease of use.

Reusable insulin pens held 44.9% of Europe Insulin Pen Market revenue in 2025 and are expected to generate USD 3.34 billion by 2035. Reusable devices are gaining strategic importance because they can combine sustainability, cartridge compatibility, and premium digital features in a single platform. The category's opportunity is not limited to replacing disposable pens: connected reusable systems can become a clinical-data touchpoint that supports differentiated formulary positioning.

By Indication

Type 1 Diabetes represented 29.8% of Europe Insulin Pen Market revenue in 2025 and is expected to generate USD 1.76 billion by 2035. Type 1 Diabetes requires consistent, intensive insulin management, making reliable device usability and dose-recording capabilities clinically relevant. Smart pens are particularly well aligned with this setting because they can support multiple-daily-injection routines and facilitate conversations between patients and care teams. The European disease burden includes a substantial Type 1 population, including children and adolescents, supporting continued demand for patient-appropriate delivery options ^{[1]International Diabetes Federation. "IDF Diabetes Atlas 11th Edition — Europe Region Data." diabetesatlas.org}.

Type 2 Diabetes generated USD 1.74 billion in 2025 and is projected to account for 63.8% of Europe Insulin Pen Market revenue by 2035. Type 2 Diabetes is the market's largest indication because insulin initiation is increasingly managed across primary-care and community-pharmacy settings. The segment's trajectory will depend on treatment escalation practices, persistence with therapy, and the ability of providers to match device formats with patients' dexterity, education, and digital-engagement needs.

Gestational Diabetes held a 4.5% revenue share in 2025 and is expected to expand at a 9.5% CAGR (2026–2035). Gestational Diabetes creates a distinct device-use case in which accurate dosing, patient confidence, and short-cycle education are important. Hyperglycaemia in pregnancy affects a meaningful portion of live births in Europe, reinforcing the need for structured pregnancy diabetes-management pathways ^{[1]International Diabetes Federation. "IDF Diabetes Atlas 11th Edition — Europe Region Data." diabetesatlas.org}. Growth in screening and obstetric care coordination can therefore support pen demand despite the indication's relatively limited treatment duration.

By Distribution Channel

Retail Pharmacies generated USD 1.46 billion in 2025 and are projected to account for 45.0% of Europe Insulin Pen Market revenue by 2035. Retail pharmacies remain central to chronic insulin delivery because they combine regulated dispensing with counseling and convenient repeat access. Their role is reinforced when patients need device instruction, replacement support, or help navigating reimbursement processes, even as digitally enabled ordering captures a larger portion of repeat fulfillment.

Hospital Pharmacies accounted for 32.1% of Europe Insulin Pen Market revenue in 2025 and are expected to expand at a 4.2% CAGR (2026–2035). Hospital pharmacies remain influential in specialist-led initiation and centralized procurement, particularly for patients with complex clinical needs. However, outpatient management and community-based prescribing are gradually reducing the channel's relative role after treatment has stabilized, shifting fulfillment toward more accessible settings.

E-Commerce held 12.8% of Europe Insulin Pen Market revenue in 2025 and is projected to reach 33.1% by 2035. E-commerce is becoming more relevant for established users seeking predictable repeat fulfillment and integration with digital diabetes-management routines. The European framework for registered online medicines retailers provides an important foundation for compliant remote dispensing, including the common-logo system intended to help patients identify authorized sellers ^{[6]European Medicines Agency. "Buying medicines online — Falsified Medicines Overview." ema.europa.eu}. Digital channels are especially compatible with connected-device ecosystems that already rely on applications and remote support.

Europe Insulin Pen Market Regional Analysis

Germany

Germany is expected to generate USD 1.21 billion in insulin pen market revenue by 2035 and held a 21.9% share of the European market in 2025. Germany's scale reflects a developed reimbursement environment, broad diabetes-care infrastructure, and a sophisticated pharmacy ecosystem. It is also a key early-adoption setting for connected pen systems, where the clinical and administrative capacity to evaluate digital functionality supports manufacturers' efforts to establish premium device propositions.

UK

The UK held an 18.1% share of the market in 2025 and is expected to generate USD 0.98 billion by 2035. Universal care pathways and established pharmacy dispensing provide a durable base for insulin pen demand in the UK. Sustainability-led prescribing and outpatient management support the migration toward reusable devices, while the evolution of digital pharmacy services can expand access for patients whose treatment is managed outside specialist centers.

France

France held a 15.8% share of the market in 2025 and is expected to generate USD 0.88 billion by 2035. France combines broad reimbursement access with an established market for branded insulin-delivery systems. The country's transition toward reusable formats is supported by sustainability considerations and the gradual integration of device prescribing into community care, while hospital formularies remain influential in shaping supplier access.

Italy

Italy is expected to generate USD 0.71 billion in insulin pen market revenue by 2035 and held a 12.8% share of the European market in 2025. Italy's opportunity is tempered by variation in regional healthcare capacity and procurement execution. Northern care networks and specialist centers tend to provide more established pathways for newer devices, whereas uneven local formularies can slow the diffusion of premium formats across the broader market.

Spain

Spain is expected to generate USD 0.69 billion in insulin pen market revenue by 2035 and is projected to expand at an 8.0% CAGR (2026–2035). Spain's growth outlook is supported by wider primary-care participation in diabetes management and a sizable patient population requiring long-duration treatment. The continued development of digital fulfillment options may reinforce adoption among patients who prefer app-based interactions with chronic-care services.

Netherlands

The Netherlands held a 4.9% share of the market in 2025 and is expected to generate USD 0.28 billion by 2035. The Netherlands has outsized strategic relevance because its concentrated healthcare system, sustainability-oriented procurement, and advanced digital-health infrastructure make it a useful environment for evaluating reusable and connected pen propositions. Reimbursement decisions in this market can offer important signals for broader European commercialization strategies.

Rest of Europe

Rest of Europe held a 14.3% share of the market in 2025 and is expected to expand at a 9.3% CAGR (2026–2035). Rest of Europe encompasses markets at substantially different stages of diabetes-care development. Growth is supported by improving diagnosis, expanding healthcare access, and the modernization of procurement systems, while affordability and uneven reimbursement remain important constraints. The region offers a meaningful expansion pathway for suppliers that can balance cost-effective delivery with local regulatory and channel requirements.

Europe Insulin Pen Market Share & Competitive Landscape

The insulin pen market is highly consolidated, with the leading five players collectively accounting for approximately 88% of 2025 revenue. This Europe Insulin Pen Market share structure reflects high qualification barriers created by established formulary relationships, cartridge and device ecosystems, regulatory compliance capabilities, and the clinical evidence needed to support reimbursement. Competition consequently extends beyond pricing to include connectivity, usability, supply reliability, and access to pharmacy and hospital channels.

Novo Nordisk held approximately 35% of the European market in 2025. Its position is supported by entrenched insulin-delivery franchises, broad formulary access, and connected reusable pen offerings that reinforce its role in the transition toward data-enabled diabetes management. The company's ability to align device innovation with its diabetes-care ecosystem gives it a meaningful advantage in reimbursement discussions.

Sanofi accounted for approximately 20% of the European market in 2025. Its SoloStar and reusable pen platforms support a strong position in established European care systems, particularly where its pharmaceutical relationships and hospital-channel presence strengthen access. Connected-cap capabilities offer Sanofi a pathway to extend its delivery-device proposition without requiring an immediate wholesale shift in patient device behavior.

Eli Lilly and Company represented approximately 15% of the European market in 2025. Its pen-device franchise benefits from a broad endocrinology presence, while connected accessories offer a more incremental route to digital dose capture. That approach can be commercially relevant for systems seeking smart functionality while preserving familiar pen formats.

Becton, Dickinson and Company (BD) remains well positioned in institutional procurement through its device engineering and hospital-channel relationships. Ypsomed has a differentiated role as both a delivery-device supplier and a manufacturing partner, enabling participation in branded pharmaceutical programs as well as direct device opportunities. Owen Mumford, Medmix, and Medtronic address specialized usability, injection-platform, and connected-care needs, respectively; Medtronic's MiniMed Go Smart MDI system extends its InPen offering into an integrated smart MDI and continuous glucose monitoring proposition ^{[3]Medtronic. "Medtronic begins EMEA commercial launch of MiniMed Go Smart MDI system with Simplera sensor." minimed.com}.

B. Braun Melsungen, Biocon Biologics, and Roche Diabetes Care contribute through hospital distribution, insulin-access partnerships, and digital diabetes-management ecosystems. Emerging participants including Haselmeier and Pendiq are relevant to the innovation pipeline, particularly where dose-memory, connectivity, or adaptable pen design can meet unmet needs in specialist and digitally engaged patient populations.

Recent Industry Developments

Medtronic — EMEA Commercial Launch of MiniMed Go Smart MDI System (February 2026)

Medtronic commenced the EMEA commercial launch of its MiniMed Go Smart MDI system with the Simplera sensor in February 2026. The platform combines InPen smart insulin pen data with real-time continuous glucose monitoring in a single mobile application, with functions including dose calculations and missed-dose alerts ^{[3]Medtronic. "Medtronic begins EMEA commercial launch of MiniMed Go Smart MDI system with Simplera sensor." minimed.com}. The launch strengthens the commercial case for connected multiple-daily-injection therapy in Europe.

Go-Pen ApS — CE Mark Approval Under EU MDR Class IIb (November 2025)

Go-Pen ApS announced CE Mark approval for its user-fillable insulin pen under the EU Medical Device Regulation Class IIb framework in November 2025 ^{[4]Go-Pen ApS. "Go-Pen receives CE Mark." go-pen.com}. The approval provides a regulatory basis for European commercialization and illustrates continued innovation in user-fillable pen platforms alongside the offerings of larger established suppliers.